IDYA IDEAYA Biosciences, Inc.
Price Chart
Executive Summary
IDEAYA Biosciences is raising approximately $281.3 million in net proceeds through a public offering of 5,555,556 shares of common stock and pre-funded warrants to purchase 5,555,576 shares, priced at $27.00 per share (and $26.9999 per pre-funded warrant). The offering represents roughly 6.3% dilution to existing shareholders based on shares outstanding as of March 31, 2026, and was priced at a 14.2% discount to the last closing price of $31.48. Proceeds will fund continued clinical development and potential commercialization of darovasertib for uveal melanoma, pipeline advancement, and general corporate purposes.
Actionable Insight
The 14.2% discount to market and immediate dilution of $13.95 per share signal near-term selling pressure. Monitor for potential further equity raises given the company's pre-commercial status and broad discretion over proceeds. The underwriters' 30-day option for additional shares adds overhang. Watch for any clinical catalysts (darovasertib NDA filing in H2 2026) that could offset dilution concerns.
Key Facts
- Offering of 5,555,556 shares of common stock and pre-funded warrants to purchase 5,555,576 shares at $27.00 per share/$26.9999 per warrant
- Net proceeds of approximately $281.3 million ($323.6 million if underwriters' option exercised in full)
- Priced at a 14.2% discount to the $31.48 closing price on June 8, 2026
- Immediate dilution of $13.95 per share to new investors; as-adjusted net tangible book value increases from $10.67 to $13.05 per share
- Underwriters have a 30-day option to purchase up to 1,666,669 additional shares
- Proceeds to fund darovasertib development, pipeline advancement, and general corporate purposes
- Lock-up agreements with directors and executive officers for 60 days post-offering
Financial Impact
~$300M gross offering; ~$282M net proceeds; ~6.3% dilution to existing shareholders based on 87.9M shares outstanding pre-offering
Risk Factors
- Immediate and substantial dilution to existing shareholders ($13.95 per share)
- Potential for further equity offerings given pre-revenue status and broad capital needs
- Underwriters' option for additional shares creates near-term overhang
- No guarantee that proceeds will enhance shareholder value given management's broad discretion
- Stock price volatility common in biotechnology sector
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-264032 |
| Document: d160204dexfilingfees.htm | 0001193125-26-264032 |
| Document: 0001193125-26-264032-index-headers.html | 0001193125-26-264032 |
| Document: 0001193125-26-264032-index.html | 0001193125-26-264032 |
| Document: 0001193125-26-264032.txt | 0001193125-26-264032 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 10, 2026
2d ago
|
8-K
| $27.58 awaiting T+1 | awaiting T+1 | — | $28.98 (−5.10%) |
|
Jun 9, 2026
3d ago
|
424B5
| $28.09 awaiting T+1 | awaiting T+1 | — | $28.98 (−3.19%) |
|
Jun 8, 2026
4d ago
|
424B5
| $31.54 awaiting T+1 | awaiting T+1 | — | $28.98 (+8.12%) |
|
Jun 3, 2026
10d ago
|
8-K
| $28.40 $29.22 | ▲ +2.89% | ▲ +2.49% | $28.98 (+2.04%) |
|
May 5, 2026
5w ago
|
8-K
| $28.74 $28.24 | ▼ −1.74% | ▼ −1.41% | $28.98 (+0.84%) |
|
May 5, 2026
5w ago
|
424B5
| $28.74 $28.24 | ▼ −1.74% | ▼ −1.41% | $28.98 (+0.84%) |
|
Apr 13, 2026
8w ago
|
8-K
| $32.82 $32.35 | ▼ −1.43% | ▼ −2.64% | $28.98 (−11.70%) |
|
Apr 9, 2026
9w ago
|
8-K
| $31.00 $30.50 | ▼ −1.61% | ▼ −1.55% | $28.98 (−6.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access